Integra LifeSciences (NASDAQ:IART) Releases Earnings Results, Beats Expectations By $0.03 EPS

Posted by George Bondi on Oct 23rd, 2026

Integra LifeSciences (NASDAQ:IART – Get Free Report) released its earnings results on Wednesday. The life sciences company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03, FiscalAI reports. Integra LifeSciences had a return on equity of 18.74% and a net margin of 0.79%. The company had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. During the same quarter in the previous year, the company posted ($0.07) EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

Cincinnati disruption worsened, reducing third-quarter revenue by approximately $7 million and expected to cut fourth-quarter revenue by another $15 million-$20 million. Full manufacturing operations for the MAYFIELD product family are not expected until the second quarter of 2027.
Specialty Surgery remained resilient, with organic revenue growth of 4.2% and neurosurgery growth of 6.5% despite the Cincinnati headwind. Management cited continued momentum in CereLink, Certas Plus, Bactiseal, DuraSeal, cranial perforators, and international markets.
Tissue Reconstruction declined 2.2% organically, pressured by MicroMatrix/UBM competition and slower share recovery for certain Integra Skin products. Management expects base Tissue Reconstruction revenue to remain approximately flat in 2027, although SurgiMend should provide incremental growth after its planned December relaunch.
Cash generation and balance-sheet flexibility improved, with record quarterly operating cash flow of $96 million, leverage reduced to 3.8 times, and $46 million of debt repaid. The completed $2.1 billion refinancing extends maturities and increases covenant capacity, though it will add approximately $24 million of annual interest expense in 2027.
Full-year 2026 guidance remains revenue of $1.634 billion-$1.654 billion and adjusted EPS of $2.30-$2.40, while fourth-quarter revenue is expected to decline year over year at the midpoint. Management expects 2027 revenue and EPS growth, but acknowledged headwinds from Cincinnati, tariffs, higher interest expense, and slower Tissue Reconstruction recovery.

Integra LifeSciences Trading Down 3.6%

NASDAQ IART traded down $0.44 during trading on Friday, hitting $11.88. The company had a trading volume of 83,952 shares, compared to its average volume of 910,878. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a one year low of $8.70 and a one year high of $20.49. The company has a market cap of $923.60 million, a price-to-earnings ratio of -131.94, a price-to-earnings-growth ratio of 0.64 and a beta of 1.21. The company’s fifty day moving average is $15.44 and its 200-day moving average is $15.58.

Analysts Set New Price Targets

A number of brokerages have commented on IART. Citizens Jmp decreased their price target on Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Thursday. Truist Financial dropped their price objective on Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating for the company in a research note on Wednesday, October 14th. JPMorgan Chase & Co. cut their target price on shares of Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating on the stock in a report on Thursday. Citigroup restated an “outperform” rating on shares of Integra LifeSciences in a report on Thursday. Finally, Wells Fargo & Company set a $13.00 target price on shares of Integra LifeSciences and gave the stock an “equal weight” rating in a research note on Thursday. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $17.00.

Get Our Latest Stock Analysis on Integra LifeSciences

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

Positive Sentiment: Integra reported third-quarter adjusted EPS of $0.59, exceeding the $0.56 consensus estimate and improving from a loss of $0.07 in the year-ago quarter. Integra Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Positive Sentiment: Citizens JMP maintained a “market outperform” rating despite reducing its price target from $25 to $22, implying substantial upside if Integra’s operational issues improve. Integra LifeSciences PT Lowered to $22 at Citizens on Specialty Surgical Business Headwinds
Neutral Sentiment: Citigroup lowered its target from $15 to $14 and kept a “neutral” rating, signaling limited conviction while still seeing potential recovery upside. Citigroup analyst recommendations
Neutral Sentiment: JPMorgan reduced its target from $17 to $14 and retained an “underweight” rating, reflecting a more cautious view of Integra’s outlook. JPMorgan analyst recommendations
Negative Sentiment: Third-quarter revenue of approximately $411.2 million fell short of estimates near $413.2 million, while quarterly revenue guidance reportedly missed expectations. Flooding and operational disruption in Cincinnati, along with weakness in the tissue-reconstruction business, weighed on the outlook. Integra Life falls as tissue reconstruction woes add to flooding worries in Q3
Negative Sentiment: Investors are also scrutinizing Integra’s $2.1 billion refinancing. The reduction in its revolving credit commitment from $1.3 billion to $600 million has revived concerns about leverage, liquidity and future refinancing flexibility. Integra LifeSciences’ $2.1B Refinancing Merits a Closer Look
Negative Sentiment: Several law firms have announced investigations into potential securities-law violations related to Integra’s disclosures. These announcements do not establish wrongdoing, but they add legal uncertainty and negative sentiment. Frank R. Cruz investigation announcement

About Integra LifeSciences

(Get Free Report)

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.